CClinicalTrials.gg
TerminatedNCT03705273Updated Nov 8, 2021Results posted

Comparison of Dexamethasone Oral Preparations to Assess Taste and Acceptance in Children With Asthma and Croup

A Phase 4 interventional study of Dexamethasone IV for PO and Dexamethasone crushed tablets in Asthma and Croup, sponsored by Vanderbilt University Medical Center. Terminated at 1 site in United States. Open to participants aged 1 Year to 7 Years. Per ClinicalTrials.gov, last updated 2021-11-08.

Sponsored by Vanderbilt University Medical Center · Phase 4, Interventional, and Treatment

Why this study was terminated
Dr. Arnold assisted in designing and initiating study for a pharmacology PhD candidate. The candidate left the institution and study enrollment was terminated.
Phase
Phase 4
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
1 Year to 7 Years
Sex
All
01

Study summary

Study of the palatability and acceptability of dexamethasone oral tablets crushed and placed in apple sauce or pudding in comparison with the IV solution mixed with sugar syrup and given orally. It is hypothesized that dexamethasone tablets crushed and administered in apple sauce or pudding will be more palatable and acceptable for pediatric patients receiving dexamethasone for an acute asthma exacerbation or croup.

02

Conditions studied

  • Asthma
  • Croup

Browse trials for

03

Who can participate

Ages eligible
1 Year to 7 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Diagnosis of acute asthma exacerbation or croup (laryngotracheitis) in the Vanderbilt Children's Hospital Emergency Department
  • Age 1 to 7 years
  • Dexamethasone treatment indicated
  • No other acute or chronic process accounting for signs and symptoms (e.g., foreign body aspiration, pneumonia, cystic fibrosis)
  • Have not received systemic corticosteroid for current episode prior to enrollment

Exclusion criteria

Exclusion Criteria:

  • Allergy to dexamethasone or apple sauce and pudding
  • Unable to take medication orally
04

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Dexamethasone IV for PO

    Dexamethasone IV for PO solution mixed with sugar syrup to be given orally

    Drug: Dexamethasone IV for PO

  • Active comparator
    Dexamethasone crushed tablets

    Dexamethasone tablet crushed and placed in apple sauce or pudding to be given orally

    Drug: Dexamethasone crushed tablets

Interventions

  • DrugDexamethasone IV for PO

    Common pediatric emergency department practice

    Also known as: Dexamethasone injection

  • DrugDexamethasone crushed tablets

    Alternative route of administration for patients unable to swallow tablet whole

    Also known as: Dexamethasone oral tablet

05

What researchers measure

Primary outcomes

  1. Number of Participants With Nausea

    Presence of nausea after medication administration (yes/no) measured by participant self-report

    Time frame: 1 hour

Secondary outcomes

  1. Number of Participants Requiring Second Dose of Dexamethasone

    Reason for patient needing a second dose of dexamethasone; such as spit dose up or vomiting dose

    Time frame: 1 hour

06

Results

Posted Nov 8, 2021

Participant flow

Forty participants were enrolled and randomized, of which 20 were randomized to receive dexamethasone tablets.

Participant flow — Overall Study
MilestoneDexamethasone TabletsDexamethasone-IV Solution-in-syrup
Started2020
Completed2020
Not completed00

Outcome measures

PrimaryNumber of Participants With Nausea

Presence of nausea after medication administration (yes/no) measured by participant self-report

Time frame:
1 hour
Reported as:
Count of participants · Participants
Number of Participants With Nausea
ParticipantsDexamethasone TabletsDexamethasone IV for PO
Number of Participants With Nausea30
SecondaryNumber of Participants Requiring Second Dose of Dexamethasone

Reason for patient needing a second dose of dexamethasone; such as spit dose up or vomiting dose

Time frame:
1 hour
Reported as:
Count of participants · Participants
Number of Participants Requiring Second Dose of Dexamethasone
ParticipantsDexamethasone TabletsDexamethasone IV for PO
Number of Participants Requiring Second Dose of Dexamethasone00

Adverse events

Collected over Time of randomization up to one hour after last dose of treatment. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dexamethasone IV for PO0/20 (0%)0/20 (0%)0/20 (0%)
Dexamethasone Crushed Tablets0/20 (0%)0/20 (0%)0/20 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)Dexamethasone IV for PODexamethasone Crushed TabletsTotal
Mean2.75 ± 1.882.70 ± 1.922.75 ± 1.88
Sex: Female, Male
Sex: Female, Male(Participants)Dexamethasone IV for PODexamethasone Crushed TabletsTotal
Female71219
Male13821
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Dexamethasone IV for PODexamethasone Crushed TabletsTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American151530
White5510
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Dexamethasone IV for PODexamethasone Crushed TabletsTotal
United States202040
Diagnosis asthma
Diagnosis asthma(Participants)Dexamethasone IV for PODexamethasone Crushed TabletsTotal
Count of participants151631
Diagnosis croup
Diagnosis croup(Participants)Dexamethasone IV for PODexamethasone Crushed TabletsTotal
Count of participants549
07

Study locations

1 site
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
08

References and documents

Study documents

  • Protocol and statistical analysis plan · Sep 19, 2018

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: Undecided

09

Registry details

Key details

Study ID
NCT03705273
Lead sponsor
Vanderbilt University Medical Center
Responsible party
Donald H Arnold (Professor of Pediatrics, Vanderbilt University Medical Center) — Principal investigator
First posted
Oct 15, 2018
Start date
Oct 23, 2018
Primary completion
Oct 2, 2020
Completion
Oct 2, 2020
Results posted
Nov 8, 2021
Last update
Nov 8, 2021

Study contacts

Donald Arnold, MD, MPH
principal investigator · Vanderbilt University Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion